By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them.

Reject
United Kingdom | EnglishEN

Current country and language: United KingdomUnited Kingdom | English (EN)

ChinaChina
GermanyGermany
IrelandIreland
ItalyItaly
SpainSpain
United KingdomUnited Kingdom

YOU ARE LEAVING THE CURRENT LANGUAGE


Breathing life into medicines

Business Development

We have strong track record of successful acquisitions, having completed 34 acquisitions and a number of in-licensing deals over the past 16 years, with a combined deal value of over £250 million.

Alliance’s growth strategy is underpinned by a continuing focus on acquisitions and in-licensing opportunities, in order to bring new products into the business. 

To enable us to deliver on our strategy, the group has a dedicated Business Development team who actively seek out acquisition and licensing opportunities.  We have considerable expertise in target selection, contract negotiation and integration of acquired products into our business operations.

A history of sales stability or the potential for growth is our primary interest when assessing acquisition opportunities.

We also have considerable financial resources available to enable us to fund future deals. 

If you have a business development opportunity you’d like to discuss, please email us at bd@alliancepharmaceuticals.com or call our switchboard on +44 (0) 1249 466966.
 

Deal History

Juni 2018

Nizoral

Dezember 2017

Vamousse

Dezember 2017

Ametop Gel 4% w/w

Dezember 2015

Sinclair Healthcare Products

Februar 2015

MacuVision

Mehr erfahren